B3-pcbanner.jpg B3-phbanner.jpg
Ribo and Asymchem signed a cooperation agreement to build a production commercialization base for oligonucleotide therapeutic drug substance
Jan 10,2021

Today Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as Ribo or the Company) signed a strategic cooperation agreement with Haihe Asymchem Fund and Asymchem, Inc. (Asymchem) for the oligonucleotide therapeutic production and construction project. The three parties will build a kilogram-level commercial-scale production base of oligonucleotide therapeutic drug substance in the Tianjin Economic-Technological Development Area. Using the BOT (Build-Operate-Transfer) model, Asymchem will provide one-stop services for the project.

Deployment in oligonucleotide therapeutic production and supply chain is the key initiative of Ribo to promote the industrialization process. The strategic cooperation with Haihe Asymchem Fund and Asymchem—a leading CDMO service provider—for the large-scale production of oligonucleotide therapeutic drug substance is the starting point for Ribo's deployment in the upstream portion of the supply chain. The cooperation will provide strong support for clinical studies and commercialized production of oligonucleotide therapeutics.